Pharmaceutical tablet with PVP having enhanced drug dissolution rate
US5262171A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 25, 1991 |
| Grant date | Nov 16, 1993 |
| Priority date | — |
| Expiry date | Nov 25, 2011 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S526/936
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical tablet is provided herein having an effective dissolution rate. The tablet contains a pharmaceutically-active ingredient and a substantially linear, i.e. non-crosslinked K-30 to K-120 PVP as a binding agent. The PVP used herein is made by an initiated polymerization process in which vinyl pyrrolidone monomer is polymerized in the presence of an initiator which produces a linear PVP polymerization, i.e. is a poor hydrogen abstractor of PVP polymer backbones, which would produce a disadvantageous crosslinked PVP product. Suitable initiators include low energy peroxyester free radical initiators, such as t-amylperoxy pivalate, an azo initiator, or a redox initiator which can perform at low temperatures. Preferably the residual initiator level in the PVP is reduced to less than 500 ppm, thereby further precluding the possibility of crosslinking of the PVP polymer during the shelf-life of the tablet.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.